We’re not chasing sci‑fi. We’re “inventing the imaginable”: unlocking proteins we already know patients need, but we still struggle to manufacture reliably. @tombergk sat down with @fiftyyears on Happy Warriors to share the why, the how, and the hard lessons of building it.

CEO of Campus-based @expressionedits Kärt Tomberg shares her founder journey in this excellent documentary from @fiftyyears - ow.ly/qRoT50YhtFb

Take a look inside the lab of Campus-based @expressionedits in this great first episode of Wilbe Stories: Founder Series from @wilbe_science. youtube.com/watch?v=VYo8M4Qt…

In this conversation with @fiftyyears, I share how one uncomfortable “this doesn’t make sense” moment turned into a company: @ExpressionEdits.

Meet Kärt of @expressionedits, she's amazing 🥹 youtu.be/VYo8M4QtaIc

🚀 Join us on 22nd May for the return of Start-up Festival ➡️ ow.ly/p7bR50VxZlf Our expert panel will dive into what’s working for start-ups in 2025, including trends, challenges, and real-world wins. 💡 🔺 Rebecca Godfrey PhD, COO, @expressionedits 🔺 Özgür Tuncer, CEO & Executive Director, @Stablepharma1 🔺 Carolyn Porter, CEO, Outrun Therapeutics Find out more 👉 ow.ly/p7bR50VxZlf

Campus-based @expressionedits has appointed Dr Amrik Basran as Chief Scientific Officer to lead the translation of its intronization technology into a pipeline of innovative therapeutics, starting with recombinant protein therapeutics. Full story 👇 ow.ly/OXGx50VjSaC

Check out this article from @CambridgeIndy covering Campus-based @expressionedits' collaboration and licensing agreement with @Boehringer ow.ly/6g0R50V6QO7

When with @tombergk we incorporated @expressionedits in 2021 I remember we published some of the early findings on @X and were flooded with expressions of interests by fellow researchers and biotech entrepreneurs to collaborate, which was great: the truest form (especially in biotech) of demonstration that what you are building has value. You want interested stakeholders to part with something of value to see you further the development of the technology. In the beginning it could be a little cash, research resources, time, brand equity. However the holy grail remains securing your first sophisticated partnership agreement with one of the dozen pharma giants and for that your proposition needs even more depth. Very proud to have had a seat to observe and share my viewpoint on this beautiful journey, very proud of Kärt's leadership and Rebecca's hustle in bagging this biggie. We are officially in business! 🫀

Campus-based @expressionedits has shared details of a collaboration and licensing agreement with @Boehringer to bring first-in-class gene therapies to patients. Full story 👉ow.ly/sTAe50UYFuZ

@expressionedits in a partnership that will focus on using its AI-based platform to design introns that improve protein expression for novel gene therapies that are being developed by @boehringerus for some undisclosed targets. hubs.li/Q036npGk0

Boehringer Ingelheim taps ExpressionEdits' AI to develop gene therapies @Boehringer @expressionedits #AI #genetherapy firstwordhealthtech.com/stor…

Hello Genetic Syntax Engine! "ExpressionEdits is essentially reintroducing punctuation into the genome’s language, creating clearer and more accurate instructions for protein production" thereby accelerating the development of gene therapies. Big news indeed for @expressionedits @Boehringer and the gene therapy space. Congratulations to @tombergk Rebecca @LeopoldParts @LilianaAntunesF and the whole Exed team 🧬

Some great new out of @expressionedits today! Can't wait to see what our introns can do in gene therapy!

The 2024 UK biotech financing report from the @BIA_UK is out highlighting the sector's innovation and global appeal. Campus-based @expressionedits and @ShiftBioscience both feature in the ranking of top seed deals. 🙌 Explore 👉 ow.ly/Ngu350UPRgT #InvestinBiotech

More coverage on @PaulBolno appointment: biopharmatrend.com/post/1083…

Super excited to welcome @WaveLifeSci CEO @PaulBolno to @Expressionedits board 🎇 businessweekly.co.uk/posts/d…